Biogen News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

28.10.13	Pre-market Movers For Oct 28 (BIIB, MRK, MOS, BKW, DNDN, CLVS, SOHU, CYOU, SNTA) (RTTNews)
28.10.13	Aktien New York Ausblick: Wenig bewegt vor Daten und Fed-Sitzung (dpa-afx)
28.10.13	Biogen Tops Estimates On MS Drug Sales, Boosts 2013 Outlook (RTTNews)
28.10.13	Für Biogen Idec zahlt sich Kampf gegen MS weiter aus - Prognose erhöht (dpa-afx)
28.10.13	Biogen Idec Q3 Profit Rises; Lifts Full Year Guidance - Quick Facts (RTTNews)
28.10.13	Earnings Watch For October 28 (MRK, PMCS, STX, SANM, AAPL, PPS) (RTTNews)
11.10.13	Scheduled Earnings Releases, Survey and Study Results, and Enrollment into Clinical Trial - Research Report on Biogen Idec, Questcor, Medivation, Agenus, and Arrowhead Research (PR Newswire)
08.10.13	Critical Alerts For Coca-Cola, Biogen Idec, Hewlett-Packard, Yum! Brands, and Sarepta Therapeutics Released By InvestorsObserver (PR Newswire)
04.10.13	Conference Calls, Philanthropic Activities, Clinical Trial Data, and Regulatory Approvals - Research Report on Celgene, UnitedHealth, Biogen Idec, WellPoint, and Medtronic (PR Newswire)
04.10.13	New TECFIDERA® (Dimethyl Fumarate) Data Show Sustained Efficacy and Long-Term Safety in a Broad Range of Multiple Sclerosis Patients (Businesswire)
03.10.13	Biogen Idec: New Analyses Show Tysabri Given Earlier Reduces MS Disease Activity (RTTNews)
03.10.13	New TYSABRI® Data Show Earlier Treatment and Longer-Term Use Result in Significant Reductions in MS Disease Activity (Businesswire)
02.10.13	Presentation on Research Findings, Recognitions, Clinical Trial Results, and Orphan Drug Designations - Research Report on Celgene, Biogen Idec, Amgen, Nektar, and Zalicus (PR Newswire)
01.10.13	Biogen Says New Data Show Significant Improvements With Plegridy (RTTNews)
01.10.13	Neue Auswertungen von Studiendaten zeigen signifikante klinische und kernspintomographische Verbesserungen bei Behandlung mit PLEGRIDY™ (Peginterferon Beta-1a) (Businesswire)
01.10.13	New Data Analyses Show Significant Clinical and MRI Improvements with PLEGRIDY™ (Peginterferon Beta-1a) (Businesswire)
24.09.13	Biogen Idec Becomes First U.S.-Based Biotech Named to Dow Jones Sustainability World Index (Businesswire)
24.09.13	Biogen Idec als erstes US-Biotech-Unternehmen in Dow Jones Sustainability World Index aufgenommen (Businesswire)
23.09.13	Biogen Idec stellt umfangreiche neue Daten zu seinem robusten Portfolio für multiple Sklerose auf dem ECTRIMS-Kongress vor (Businesswire)
23.09.13	Biogen Idec to Present Extensive New Data from Its Robust Multiple Sclerosis Portfolio at ECTRIMS (Businesswire)
20.09.13	Biogen Idec Employees Participate in Third Annual "Care Deeply Volunteer Day” (Businesswire)
20.09.13	Mitarbeiter von Biogen Idec nehmen am dritten jährlichen "Care Deeply Volunteer Day" teil (Businesswire)
16.09.13	Collaborations, New Studies, and New Drug Applications - Research Report on Amgen, Gilead, Abbott, Biogen Idec, and UnitedHealth (PR Newswire)
12.09.13	FDA Approvals, Study Results, Multi-Year Collaborations, Data Presentations, and Supply Agreements - Research Report on Celgene, Amgen, Biogen Idec, Vertex, and Illumina (PR Newswire)
09.09.13	Biogen, Isis Pharma Collaborate On Advance Treatment Of Neurological Disorders (RTTNews)
06.09.13	Critical Alerts For Visa, Biogen, Union Pacific, Hewlett Packard, and Universal Display Corp Released By InvestorsObserver (PR Newswire)
03.09.13	Pharmaceuticals Report Revolutionary Findings, Approved Treatments, Investor Conferences - Research Report on Celgene, Amgen, Biogen Idec, Regeneron, and Questcor (PR Newswire)
06.08.13	Critical Alerts For Visa, Biogen, TJX, Newmont Mining, and Mens Wearhouse Released By InvestorsObserver (PR Newswire)
01.08.13	Celgene Corporation -- Moody's rates Celgene's new notes Baa2; positive outlook (Moodys)
01.08.13	M&As, Strong Earnings, and Share Repurchase Programs Support Optimism for Healthcare - Research Report on Perrigo, Intuitive Surgical, Biogen Idec, Celgene, and Lilly (PR Newswire)
29.07.13	Perrigo Company -- Moody's affirms Perrigo's Baa3 rating following Elan acquisition announcement (Moodys)
29.07.13	Perrigo Agrees To Buy Elan In $8.6 Bln Cash And Stock Deal (RTTNews)
25.07.13	Pre-market Movers For July 25 (GM, FB, BSX, BIIB, CELG, SI) (RTTNews)
25.07.13	Biogen Idec/Kampf gegen Multiple Sklerose zahlt sich aus - Prognose erhöht (AWP)
25.07.13	Für Biogen Idec zahlt sich Kampf gegen Multiple Sklerose aus - Prognose erhöht (dpa-afx)
25.07.13	Biogen Idec Posts Higher Q2 Profit; Ups Annual Targets - Quick Facts (RTTNews)
25.07.13	Earnings Watch For July 25 (MMM, CCE, GM, AMZN, SBUX, BMY, DHI) (RTTNews)
24.07.13	Marketing Applications, Product Launches, Commencement of Studies, Collaborations, and Release of Funding - Research Report on Biogen Idec, Illumina, Santarus, Celsion, and BioCryst (PR Newswire)
19.07.13	Biogen: US And EU Regulators Accept Plegridy Marketing Applications For Review (RTTNews)
19.07.13	US and EU Regulatory Authorities Accept PLEGRIDY™ (peginterferon beta-1a) Marketing Applications for Review (Businesswire)
16.07.13	Gericht verweigert Genentech Anhörung (AWP)
16.07.13	SMI im Minus -- Dow gibt moderat nach -- Yahoo schrumpft unter Marissa Mayer -- Reding: Troika gehört abgeschafft -- Europas Börsen mit Verlusten -- L'Oreal steigert Umsatz stärker als erwartet (finanzen.ch)
16.07.13	Genentech, Biogen Idec Refused Re-hearing In Arzerra Patent Infringement Case (RTTNews)
04.07.13	Biogen Idec and Sobi Present New Data from the Phase 3 Study of Their Long-Lasting Hemophilia Factor Candidate ELOCTATE™ (Businesswire)
04.07.13	Merck KGaA -- Moody's upgrades Merck KGaA to A3; stable outlook (Moodys)
04.07.13	Biogen, Sobi Present Data Supporting Clinical And Safety Profile Of ELOCTATE (RTTNews)
02.07.13	Biogen Idec and Sobi Present New Data from the Phase 3 Study of Their Long-Lasting Hemophilia Factor Candidate ALPROLIX™ (Businesswire)
30.05.13	Aktien New York Ausblick: Freundlich nach Vortagesminus - Daten im Blick (dpa-afx)
20.05.13	Wall Street Schluss: Etwas leichter -- Öl dreht ins Plus -- Euro nähert sich 1,29-Grenze -- Ryanair im Hoch -- Euro tritt auf der Stelle -- Dax endet auf Rekordhoch (finanzen.ch)
17.05.13	USA: Genentech und Biogen Idec wollen neue Anhörung (AWP)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	74.30	1.53 %	K V
Holcim	87.38	1.49 %	K V
Roche Hldg G	251.00	1.46 %	K V
Swiss Re	130.35	1.44 %	K V
UBS Group	27.07	1.35 %	K V
Swisscom	501.00	0.52 %	K V
Lonza Grp	532.40	0.26 %	K V
Nestle	74.08	0.14 %	K V
Sonova Hldg	295.60	0.00 %	K V
Geberit	512.20	-0.39 %	K V

mehr

24.12.24		Börse New York: Dow Jones zeigt sich zum Handelsende fester
24.12.24		Zuversicht in New York: Dow Jones am Dienstagnachmittag mit Gewinnen
24.12.24		Dow Jones-Handel aktuell: Dow Jones steigt am Dienstagmittag
24.12.24		Börse New York: NASDAQ 100-Anleger greifen am Dienstagmittag zu
24.12.24		Freundlicher Handel: Letztendlich Gewinne im Euro STOXX 50
24.12.24		Dienstagshandel in New York: NASDAQ 100 startet in der Gewinnzone
24.12.24		NYSE-Handel: Dow Jones beginnt Dienstagshandel mit Gewinnen